Syed Haider
Lansing, MINPI 1366096752
Payments from drug & device makers
What this record shows
This record is dominated by grants: $7,650 of the $10,848 with a category attached, or 70.5%. Abbott accounts for 70.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $4,829 and has fallen 51.6% since, to $2,338 in 2025.
Across 94 payments — averaging $115.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Medtronic$1K
- Amgen$566
- E.r. Squibb & Sons, L.L.C.$308
- Pfizer$290
- AstraZeneca$246
- plus $688 from 13 others
What the payments were for
- Grants$7,65071%
- Travel & lodging$8228%
- Food & beverage$2,37622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $7,674 |
| Medtronic | 8 | $1,077 |
| Amgen | 24 | $566 |
| E.r. Squibb & Sons, L.L.C. | 16 | $308 |
| Pfizer | 13 | $290 |
| AstraZeneca | 3 | $246 |
| Alnylam Pharmaceuticals Inc. | 5 | $216 |
| Edwards Lifesciences | 1 | $99 |
| Lexicon Pharmaceuticals, Inc. | 2 | $51 |
| Boston Scientific | 3 | $50 |
| Boehringer Ingelheim | 2 | $42 |
| Bayer | 2 | $40 |
| Johnson & Johnson | 2 | $37 |
| Novartis | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Terumo Medical Corporation | 1 | $26 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Abiomed | 1 | $21 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASSURITY$1,575
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$1,575
- TACTICATH$1,000
- Micra$134
- LOKELMA$107
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 27 | $21,077 |
| EliquisApixaban | 24 | $15,143 |
| EntrestoSacubitril/Valsartan | 12 | $7,493 |
| Metoprolol Succinate | 64 | $914 |
| Prasugrel Hcl | 20 | $799 |
| ClopidogrelClopidogrel Bisulfate | 17 | $553 |
| Atorvastatin Calcium | 34 | $468 |
| Losartan Potassium | 17 | $179 |
| Amlodipine Besylate | 16 | $147 |
| Lisinopril | 12 | $125 |
| Carvedilol | 13 | $120 |
| Spironolactone | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $246 | $21,07727 claims |
| PfizerEliquis | $290 | $15,14324 claims |
| NovartisEntresto | $33 | $7,49312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.